Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study

Marc Brusosa, Sonia Ruiz,Inés Monge,María Teresa Solano,Laura Rosiñol,Jordi Esteve,Enric Carreras,M. Ángeles Marcos,Gisela Riu,Esther Carcelero, Carmen Martinez,Francesc Fernández-Avilés,Montserrat Rovira,María Suárez-Lledó,María Queralt Salas

Annals of Hematology（2023）

Cited 0|Views15

No score

Abstract

Letermovir for CMV prevention in CMV-seropositive adults undergoing allo-HCT was implemented at our program in 2021. This study investigates the results from the use of letermovir. The study includes all the 140 CMV-seropositive patients who underwent an allo-HCT during the years 2020, 2021, and 2022 at our institution. Thirty-eight (27.4

Translated text

Key words

Letermovir,Cytomegalovirus,Prophylaxis,Allogeneic hematopoietic cell transplantation,CMV reactivation,CMV disease

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined